Autochthonous acute hepatitis E: treatment with sofosbuvir and ribavirin

被引：22
|
作者：
Biliotti, Elisa [1 ]
Franchi, Cristiana [1 ]
Spaziante, Martina [1 ]
Garbuglia, Anna Rosa [2 ]
Volpicelli, Lorenzo [1 ]
Palazzo, Donatella [1 ]
De Angelis, Maurizio [1 ]
Esvan, Rozenn [1 ]
Taliani, Gloria [1 ]
机构：
[1] Sapienza Univ Rome, Clin Trop Med, Dept Clin Med, Rome, Italy
[2] Natl Inst Infect Dis Lazzaro Spallanzani, Lab Virol, Rome, Italy
来源：
INFECTION | 2018年 / 46卷 / 05期
关键词：
Hepatitis E; Ribavirin; Sofosbuvir; Acute-on-chronic-liver-failure; Hepatitis C; E VIRUS-INFECTION; PATIENT;
D O I：
10.1007/s15010-018-1168-7
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
IntroductionHepatitis E virus (HEV) is an emerging cause of autochthonous-acute-hepatitis and acute-on-chronic-liver-failure in western countries. Treatment is not routinely used, despite ribavirin has a good antiviral effect. In vitro sofosbuvir inhibits HEV replication, but clinical data are lacking.Case reportWe report a case of acute-on-chronic-liver-failure due to HEV treated with sofosbuvir and ribavirin. Thetreatment was capable of rapidly inducing both HCV and HEV viral suppression.ConclusionIn conclusion, although more data are required before firm conclusions could be drawn, the combination of sofosbuvir and ribavirin in not immunosuppressed patients with acute hepatitis E may be able to clear HEV infection.
引用
收藏
页码：725 / 727
页数：3
相关论文
共 50 条
  • [31] Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective
    Todesco, Eve
    Mazzola, Alessandra
    Akhavan, Sepideh
    Abravanel, Florence
    Poynard, Thierry
    Roque-Afonso, Anne-Marie
    Peytavin, Gilles
    Marcelin, Anne-Genevieve
    Calmus, Yvon
    Lecuyer, Lucien
    Guillemain, Romain
    Conti, Filomena
    ANTIVIRAL THERAPY, 2018, 23 (05) : 463 - 465
  • [32] Neurologic Disorders in Immunocompetent Patients with Autochthonous Acute Hepatitis E
    Perrin, H. Blasco
    Cintas, P.
    Abravanel, F.
    Gerolami, R.
    d'Alteroche, L.
    Raynal, J. -N.
    Alric, L.
    Dupuis, E.
    Prudhomme, L.
    Vaucher, E.
    Couzigou, R.
    Liversain, J. -M.
    Bureau, C.
    Vinel, J. -P.
    Kamar, N.
    Izopet, J.
    Peron, J. -M.
    EMERGING INFECTIOUS DISEASES, 2015, 21 (11) : 1928 - 1934
  • [33] Ribavirin for severe acute hepatitis E virus infection
    Madureira, Sergio
    Soares, Neuza
    Lino, Rita
    Almeida, Catarina
    Ceia, Filipa
    Silva-Pinto, Andre
    Albuquerque, Ines
    Almeida, Jorge
    GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, 2022, 181 (09) : 680 - 683
  • [34] Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
    Sulkowski, Mark S.
    Naggie, Susanna
    Lalezari, Jacob
    Fessel, Walford Jeffrey
    Mounzer, Karam
    Shuhart, Margaret
    Luetkemeyer, Anne F.
    Asmuth, David
    Gaggar, Anuj
    Ni, Liyun
    Svarovskaia, Evguenia
    Brainard, Diana M.
    Symonds, William T.
    Subramanian, G. Mani
    McHutchison, John G.
    Rodriguez-Torres, Maribel
    Dieterich, Douglas
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (04): : 353 - 361
  • [35] Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of Fibrosing Cholestatic Hepatitis C After Liver Transplantation
    Everson, Gregory T.
    Forns, Xavier
    Mutimer, David
    Manns, Michael P.
    Reddy, K. Rajender
    Flamm, Steven L.
    Denning, Jill
    Arterburn, Sarah
    Brandt-Sarif, Theo
    Pang, Phil
    McHutchison, John G.
    Afdhal, Nezam H.
    Charlton, Michael R.
    Samuel, Didier
    Gane, Edward
    TRANSPLANTATION, 2015, 99 : 101 - 101
  • [36] Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin
    Globke, Brigitta
    Raschzok, Nathanael
    Teegen, Eva-Maria
    Pratschke, Johann
    Schott, Eckart
    Eurich, Dennis
    TRANSPLANT INFECTIOUS DISEASE, 2017, 19 (01)
  • [37] Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of Fibrosing Cholestatic Hepatitis C After Liver Transplantation
    Everson, Gregory T.
    Forns, Xavier
    Mutimer, David
    Manns, Michael P.
    Reddy, K. Rajender
    Flamm, Steven L.
    Denning, Jill
    Arterburn, Sarah
    Brandt-Sarif, Theo S.
    Pang, Phil
    McHutchison, John G.
    Afdhal, Nezam H.
    Charlton, Michael R.
    Samuel, Didier
    Gane, Edward
    GASTROENTEROLOGY, 2015, 148 (04) : S1086 - S1087
  • [38] Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C
    Rivero-Juarez, Antonio
    Brieva, Teresa
    Frias, Mario
    Rivero, Antonio
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (09) : 901 - 910
  • [39] Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir-ribavirin
    Todesco, Eve
    Demeret, Sophie
    Calin, Ruxandra
    Roque-Afonso, Anne-Marie
    Thibault, Vincent
    Mallet, Vincent
    Akhavan, Sepideh
    Jaspard, Marie
    Peytavin, Gilles
    Poynard, Thierry
    Katlama, Christine
    Pourcher, Valerie
    AIDS, 2017, 31 (09) : 1346 - 1348
  • [40] The challenge of chronic hepatitis E in liver transplant recipients: Failure of sofosbuvir plus ribavirin therapy
    Sastre, Lydia
    Garcia-Lopez, Mireia
    Perez-del-Pulgar, Sofia
    Lens, Sabela
    Costa, Josep
    Navasa, Miguel
    Forns, Xavier
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2020, 43 (03): : 136 - 137
12345